- Home
- DEA vs COLL Comparison
DEA vs COLL Comparison
Compare DEA & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEA
- COLL
- Stock Information
- Founded
- DEA 2011
- COLL 2002
- Country
- DEA United States
- COLL United States
- Employees
- DEA N/A
- COLL N/A
- Industry
- DEA Real Estate Investment Trusts
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- DEA Real Estate
- COLL Health Care
- Exchange
- DEA Nasdaq
- COLL Nasdaq
- Market Cap
- DEA 1.0B
- COLL 958.8M
- IPO Year
- DEA 2015
- COLL 2015
- Fundamental
- Price
- DEA $21.91
- COLL $33.37
- Analyst Decision
- DEA Hold
- COLL Strong Buy
- Analyst Count
- DEA 5
- COLL 4
- Target Price
- DEA $27.15
- COLL $44.25
- AVG Volume (30 Days)
- DEA 468.0K
- COLL 401.3K
- Earning Date
- DEA 11-04-2025
- COLL 11-06-2025
- Dividend Yield
- DEA 8.21%
- COLL N/A
- EPS Growth
- DEA N/A
- COLL N/A
- EPS
- DEA 0.38
- COLL 1.06
- Revenue
- DEA $322,861,000.00
- COLL $707,007,000.00
- Revenue This Year
- DEA $8.62
- COLL $22.23
- Revenue Next Year
- DEA $6.59
- COLL $2.78
- P/E Ratio
- DEA $58.00
- COLL $31.62
- Revenue Growth
- DEA 7.93
- COLL 22.61
- 52 Week Low
- DEA $19.33
- COLL $23.23
- 52 Week High
- DEA $36.31
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- DEA 37.01
- COLL 36.46
- Support Level
- DEA $22.39
- COLL $34.19
- Resistance Level
- DEA $22.89
- COLL $35.83
- Average True Range (ATR)
- DEA 0.43
- COLL 1.03
- MACD
- DEA -0.12
- COLL -0.29
- Stochastic Oscillator
- DEA 5.31
- COLL 6.56
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.